By HospiMedica International staff writers Posted on 14 Oct 2020 Image: Colorized scanning electron micrograph of a cell (purple) heavily infected with SARS-CoV-2 virus particles (yellow) (Photo courtesy of National Institute of Allergy and Infectious Diseases, National Institutes of Health) A recent study has shown that blocking a specific protein in a biological pathway may prevent SARS-CoV-2 infection and keep the virus from misdirecting the immune system against healthy cells and organs. While the world waits eagerly for a safe and effective vaccine to prevent infections from SARS-CoV-2, the virus behind the COVID-19 pandemic, researchers also are focusing on better understanding how SARS-CoV-2 attacks the body in the search for other means of stopping its devastating impact. The key to one possibility – blocking a protein that enables the virus to turn the immune system against healthy cells – has been identified in a recent study by ...
Now, a new study by researchers at the University College London revealed that 86 percent of people who tested positive for COVID-19 did not have virus symptoms, such as cough, fever, and loss of taste or smell. The study findings, collected by the Office for National Statistics, the U.K. statistics body, highlight the role of asymptomatic patients in the spread of the virus. The study, published in the journal Clinical Epidemiology, utilized data from the Coronavirus Infection Survey, an extensive population-based survey looking at the link between coronavirus symptoms and test results. Over 36,000 people living in Northern Ireland, England, and Wales were included in the study, who were tested from April to June. Of the total participants, 0.32 percent of 115 people had a positive test result. From there, the team focused on these individuals to determine specific symptoms. Of the 115 people who tested positive with SARS-CoV-2, 16 ...
By HospiMedica International staff writers Posted on 31 Aug 2020 Contract tracing apps used to reduce the spread of COVID-19 are unlikely to be effective without proper uptake and support from concurrent control measures, according to a new study. Researchers at University College London (UCL, United Kingdom) conducted a systematic review of studies that examined the use of automated or partly automated contact tracing of COVID-19, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), influenza, or Ebola virus spread. The primary outcomes were the number or proportion of subsequent contacts identified; secondary outcomes included indicators of outbreak control, uptake, resource use, cost-effectiveness, and lessons learnt. In all, 4,033 papers were reviewed, of which 15 were identified with useful data. The results showed no empirical evidence of the effectiveness of automated contact tracing. Four of the seven studies suggested that to control COVID-19, high population uptake of automated contact-tracing ...
By HospiMedica International staff writers Posted on 08 Sep 2020 An antiviral treatment to be used as a topical nasal spray as prophylaxis against COVID-19 promises to be easy to use, low-cost and quickly made available over-the-counter for consumers. The Nomovid Nasal Spray developed by Parnell Pharmaceuticals (San Rafael, CA, USA) is based upon a substance licensed by the company from New Mexico Tech University to treat drug-resistant bacteria and fungi such as MRSA and Candida auris. Since it breaks down lipids in the viral envelope, Parnell tested it against the novel coronavirus. “An independent, outside laboratory has confirmed our findings and found it to be greater than 99.9% effective in vitro against the SARS-CoV-2 virus,” said Dr. Francis Parnell, Chairman and CEO of Parnell Pharmaceuticals. “Our product is based upon existing FDA approvals of the active ingredients for use in intravenous and inhalation formulations for other indications. Since the ...
By HospiMedica International staff writers Posted on 08 Sep 2020 Researchers from the University of Oxford (Oxford, UK) have found that natural infection with COVID-19 produces a robust T cell response, including inducing T cell ‘memory’ to potentially fight future infections. While research has shown that COVID-19 induces a B cell antibody response, it has been less clear whether COVID-19 causes the immune system to make virus-specific T cells too, and whether they are important for recovery from the initial infection, and protection against new infections. While antibodies latch onto and destroy disease-causing agents like viruses and bacteria, T cells latch on to diseased cells within the body, such as tumor cells or virus-infected cells. T-cells also help attract other immune cells to the area. T cells are attracted to tumor or viral protein fragments (called epitopes) displayed on the surface of diseased cells, which act like waving a flag ...
A study by the Oxford University’s Centre for Evidence-Based Medicine (Oxford, England) suggests that the current COVID-19 diagnostic tests could be too sensitive and may be detecting dead coronavirus cells, leading to overestimated infections. According to the researchers, the tests used to diagnose COVID-19 are so sensitive that they may be indicating people are infected with SARS-CoV-2 even when they had the virus 70 days ago. Prof Carl Heneghan, director of the Centre for Evidence-Based Medicine, believes that eight days after contracting COVID-19, the chances of an infected person passing on the virus to others become zero if there are no symptoms. However, fragments of the coronavirus can still remain in the body for several weeks afterwards. Polymerase chain reaction (PCR) tests currently used to detect SARS-CoV-2 have technical limitations as they cannot distinguish whether the virus in the patient is alive or dead. The researchers analyzed 25 studies on ...
By HospiMedica International staff writers Posted on 31 Aug 2020 A drug used to cure a deadly disease caused by a coronavirus in cats is expected to prove equally effective as a treatment for humans against COVID-19. Researchers at the University of Alberta (Edmonton, Alberta, Canada) are now preparing to launch clinical trials of the drug which is a protease inhibitor that interferes with the virus’s ability to replicate, thus ending an infection. Proteases are key to many body functions and are common targets for drugs to treat everything from high blood pressure to cancer and HIV. First studied by the University of Alberta researchers following the 2003 outbreak of severe acute respiratory syndrome (SARS), the protease inhibitor was further developed by veterinary researchers who showed it cures a disease that is fatal in cats. The team synthesized the compounds and tested them against the SARS-CoV-2 virus in test ...
(CNN)A Covid-19 vaccine developed by the biotechnology company Moderna in partnership with the National Institutes of Health has been found to induce immune responses in all of the volunteers who received it in a Phase 1 study.
A hospital in the US is among the first to offer rapid genome sequencing of critically ill newborns to help identify the cause of their illnesses, which could save their lives. This technology could be used on healthy babies too. But some experts raise concerns about sequencing every baby at birth.
In different parts of the world, scientists are racing to develop a vaccine for coronavirus (COVID-19). A lot is at stake as governments worldwide are in a frenzy to prevent the spread of the virus in key hotspots.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.